位置:首页 > 产品库 > Ro 31-8220
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ro 31-8220
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ro 31-8220图片
CAS NO:125314-64-9

Bisindolylmaleimide IX
Ro 31-8220 是一种有效的PKC抑制剂,对 PKCα,PKCβI,PKCβII,PKCγ,PKCε 和大鼠大脑 PKC 的IC50值为 5,24,14,27,24 和 23 nM,同时能够有效抑制 MAPKAP-K1b,MSK1,S6K1 和 GSK3β (IC50,3,8,15,38 nM), 对 MKK3,MKK4,MKK6 和 MKK7 无作用。
生物活性

Ro 31-8220 is a potentPKCinhibitor, withIC50s of 5, 24, 14, 27, 24 and 23 nM forPKCα, PKCβI, PKCβII,PKCγ,PKCεand rat brainPKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.

IC50& Target[1][2]

PKC-α

5 nM (IC50)

PKC-βII

14 nM (IC50)

PKC-βI

24 nM (IC50)

PKC-ε

24 nM (IC50)

PKC-γ

27 nM (IC50)

Rat Brain PKC

23 nM (IC50)

MAPKAP-K1b

3 nM (IC50)

MSK1

8 nM (IC50)

S6K1

15 nM (IC50)

GSK3β

38 nM (IC50)

体外研究
(In Vitro)

Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively[1]. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Moreover, Ro 31-8220 directly suppresses voltage-dependent Na+channels[2]. Ro 31-8220 (1 μM) is neuroprotective against paraoxon-induced neuronal cell death in cerebellar granule neurons, blocks paraoxon-induced caspase-3 activity, and reduces the paraoxon-induced increase in phospho-PKC pan levels[3].

体内研究
(In Vivo)

Ro 31-8220 (6 mg/kg/d, s.c.) is well tolerated, and has half-life of 5.7 hours in mice. Ro 31-8220-treated MLP–/–mice show a dramatic rescue in fractional shortening after treatment for 6 weeks, but the WT mice shows no change[4].

分子量

457.55

Formula

C25H23N5O2S

CAS 号

125314-64-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024